Warning Letter — SnugZ USA, Inc.
The FDA issued a warning letter to SnugZ USA, Inc. following an evaluation by the Center for Drug Evaluation and Research (CDER). The source indicates compliance deficiencies identified during regulatory oversight.
SnugZ USA, Inc., its manufacturing partners, and personnel responsible for CGMP compliance, quality systems, and regulatory filings for drug products.
The involvement of CDER suggests that the company's products or manufacturing processes fell under drug regulations, likely due to specific product claims or ingredients. This enforcement action indicates that the firm's quality system did not meet the required standards for drug manufacturing, which can lead to distribution interruptions or the need for significant remediation of manufacturing protocols.
Review quality agreements with contract partners to ensure defined CGMP roles and conduct a gap analysis of current manufacturing documentation against CDER standards. Ensure all products marketed with drug claims are supported by appropriate regulatory filings and manufacturing controls.
FDA Warning Letter issued to: SnugZ USA, Inc.. 09/28/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/snugz-usa-inc-735284-09282026
Open in openFDA / FDA.gov